Mathieu D, Fries D, Auer J, Bizzini B, Jacques L
Biomed Pharmacother. 1982;36(10):420-5.
The preventive effects of various doses of the immunomodulator P40 on the experimental E. coli infection of the upper and lower urinary tract have been investigated in the rat. Under our experimental conditions, P40 only weakly influenced the bacteriological picture of the infection in rats infected by the upper route. However, the development of nephropathia might be decreased. By contrast, P40 was found to prevent the development of infection in two thirds of cases infected by the lower route. The preventive effect of P40 on infections of the lower urinary tract seems to be mostly medicated by the stimulation of phagocytosis, although both humoral and cellular immunity are likely to be involved. In contrast, the defense is most probably to be ascribed to cellular immunity in infections of the upper urinary tract. For the future, conditions will have to be specified which enable P40 to express predominantly its stimulating effect on cellular immunity. Furthermore, the choice of the minimum active dose together with its fractionated administration will prevent side-effects (prostatitis) while resulting in equally pronounced protective action. Since P40 has already successfully been used in man for the treatment of both infectious and tumoral processes, it could as well be used for the prevention of relapses in recurrent urinary infections.
已在大鼠中研究了不同剂量免疫调节剂P40对实验性上、下尿路感染大肠杆菌的预防作用。在我们的实验条件下，P40对上尿路感染大鼠的感染细菌学情况影响微弱。然而，肾病的发展可能会减缓。相比之下，发现P40可预防三分之二下尿路感染病例的感染发展。P40对下尿路感染的预防作用似乎主要是通过刺激吞噬作用来实现的，尽管体液免疫和细胞免疫可能都参与其中。相比之下，上尿路感染的防御很可能归因于细胞免疫。未来，必须明确使P40主要发挥其对细胞免疫刺激作用的条件。此外，选择最小有效剂量及其分次给药将在防止副作用（前列腺炎）的同时产生同样显著的保护作用。由于P40已成功用于人类治疗感染性和肿瘤性疾病，它也可用于预防复发性尿路感染的复发。
